CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

Company Overview

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals. In addition to hematology, CRISPR Therapeutics is advancing oncology candidates such as CTX110, CTX112 and CTX120, which use engineered immune cells to target various blood cancers. The company also maintains partnerships with organizations including ViaCyte for potential treatments in type 1 diabetes, further diversifying its pipeline across therapeutic areas.

Founded in 2013 and headquartered in Zug, Switzerland, CRISPR Therapeutics maintains a significant presence in the United States, with research and development facilities in Cambridge, Massachusetts. The company’s global footprint supports clinical trials across North America and Europe, reflecting its commitment to addressing unmet medical needs in key healthcare markets worldwide.

Under the leadership of Chief Executive Officer Samarth Kulkarni, CRISPR Therapeutics continues to expand its manufacturing capabilities and prepare for potential regulatory filings. Co-founder Emmanuelle Charpentier, a pioneer in CRISPR science, serves on the board, guiding the company’s strategic direction as it advances a novel class of genetic medicines toward commercialization.

Key Stats

• Today's Range: $52.55 to $55.85
• 50-Day Range: $44.34 to $61.74
• 52-Week Range: $34.87 to $78.48
• Volume: 1.73 million shs
• Average Volume: 1.89 million shs
• Market Capitalization: $5.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.94
• Consensus Rating: Moderate Buy

CRISPR Therapeutics Stock Analysis - MarketRank™

CRISPR Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 479th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 10 buy ratings, 5 hold ratings, and 2 sell ratings.

Upside Potential

CRISPR Therapeutics has a consensus price target of $65.94, representing about 20.3% upside from its current price of $54.83.

Amount of Analyst Coverage

CRISPR Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.07) to ($4.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CRISPR Therapeutics is -8.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CRISPR Therapeutics is -8.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CRISPR Therapeutics has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.77% of the float of CRISPR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CRISPR Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.

Change versus previous month

Short interest in CRISPR Therapeutics has recently increased by 0.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CRISPR Therapeutics does not currently pay a dividend.

Dividend Growth

CRISPR Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.39

News Sentiment

CRISPR Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 41 news articles for CRISPR Therapeutics this week, compared to 9 articles on an average week.

Search Interest

29 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.

MarketBeat Follows

27 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 440% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,578,097.00 in company stock.

Percentage Held by Insiders

4.30% of the stock of CRISPR Therapeutics is held by insiders.

Percentage Held by Institutions

69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/11/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRSP
• CIK: 1674416
• Web: www.crisprtx.com
• Phone: (141) 561-3277
• Fax: N/A
• Employees: 460
• Year Founded: 2013

Price Target and Rating

• Average Price Target for CRISPR Therapeutics: $65.94
• High Price Target: $110.00
• Low Price Target: $9.00
• Potential Upside/Downside: +20.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$581.60 million
• Net Margins: -13,856.54%
• Pretax Margin: -13,774.56%
• Return on Equity: -25.66%
• Return on Assets: -20.39%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 17.97
• Quick Ratio: 13.32

Sales & Book Value

• Annual Sales: $3.51 million
• Price / Sales: 1,506.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.81 per share
• Price / Book: 2.91

Miscellaneous

• Outstanding Shares: 96,450,000
• Free Float: 92,302,000
• Market Cap: $5.29 billion
• Optionable: Optionable
• Beta: 1.74